

Preface

This volume is comprised of a series of papers presented at the Roche-UCLA Symposium on "Monoclonal Antibodies and Cancer Therapy", held in Park City, Utah, January 26 - February 2, 1985. This meeting was attended by scientists from around the world and was the first meeting on this topic sponsored by the UCLA Symposia on Molecular and Cellular Biology.

Judging from comments and discussions during and after the meeting, it was a big success. The science was excellent and led to many useful exchanges of information among the participants. This certainly was evident from the lengthy and thought-provoking discussions that followed every session, even after the evening programs that often lasted well after eleven o'clock. Most presentations were very well attended, although many people were exhausted by the intensity of the program and the afternoons spent skiing. The extensive and lively discussions during the plenary sessions and workshops were a tribute to the generally excellent presentations of the speakers.

Following a stimulating keynote address by Hilary Koprowski of the Wistar Institute, that defined the theme for the meeting, subjects covered dealt with many of the current issues in cancer diagnosis and therapy with monoclonal antibodies. These included the following topics: monoclonal antibodies to human cancer, human-human hybridomas, antibody therapy for leukemia and lymphoma, modulation of effector cells by monoclonal antibodies to cell surface receptors, monoclonal antibodies to lymphokines, antibody radionuclide conjugates, cancer vaccines, and monoclonal antibodies to oncogene products. Five workshop/poster sessions dealt with such topics as status of blood tests, monoclonal antibodies to premalignant cells, to conjugates with drugs or toxins, to glycolipids, and to extracellular matrix and cytoskeletal components.

A timely and thoughtful special lecture on monoclonal antibodies and cancer metastasis by I.J. Fidler, University of Texas, was the piece de resistance at the close of the meeting.

Not all the lectures and workshop presentations of the meeting are summarized in this volume since contributions herein were made voluntarily. It

is nevertheless a tribute to the speakers at the symposia that more than eighty percent of them contributed a paper to this volume which is arranged according to the organization of the meeting.

It is evident that no meeting can be successful without dedicated administrative and financial support. We would like to acknowledge the excellent assistance received from Robin Yeaton, Betty Handy and Robert Harwood and their associates in the UCLA Symposia office. We would like to express our thanks and appreciation to Hoffman-LaRoche, Inc. for its generous sponsorship of this meeting. We also would like to thank the following for their financial support: Monsanto Corporation Research Laboratories; Meloy Laboratories; Bristol-Myers Co., Pharmaceutical Research & Development Division; Damon Biotech, Inc.; E.I. duPont de Nemours & Company; Lilly Research Laboratories, Eli Lilly and Company; Boehringer-Mannheim GmbH; Pel-Freez Clinical Systems; Merck, Sharp and Dohme Research Laboratories; American Hoechst Corp; Hybritech, Inc., and Cutter Laboratories, Division of Miles Laboratories. Needless to say, without these generous contributions, the 1985 Roche-UCLA Symposium on Monoclonal Antibodies and Cancer Therapy would not have been possible.

Ralph Reisfeld, Ph.D.

Department of Immunology
Scripps Clinic & Research
Foundation
La Jolla, CA 92037

Stewart Sell, M.D.

Department of Pathology and
Laboratory Medicine
University of Texas Medical
School
P.O. Box 20708
Houston, TX 77025